Newly appointed head of drug evaluation expected to depart from FDA, according to STAT News

December 2 Richard Pazdur, the recently appointed head of the U.S. Food and Drug Administration's drug evaluation division, is reportedly preparing to retire, according to sources cited by STAT News on Tuesday.

Pazdur, a long-standing leader in oncology, assumed the position less than a month ago, succeeding George Tidmarsh, who stepped down following significant concerns about his personal behavior. During a meeting on Tuesday, Pazdur notified FDA drug center executives of his plans to leave, although he may still reverse his decision, the report added.

The Department of Health and Human Services, which supervises the FDA, has not yet commented on the situation.

Author: Logan Reeves